Evidence
Ann Clin Transl Neurol. 2024 Mar 19. doi: 10.1002/acn3.51963. Online ahead of print.
ABSTRACT
ATP1A1 encodes a sodium-potassium ATPase that has been linked to several neurological diseases. Using exome and genome sequencing, we identified the heterozygous ATP1A1 variant NM_000701.8: c.2707G>A;p.(Gly903Arg) in two unrelated children presenting with delayed motor and speech development and autism. While absent in controls, the variant occurred de novo in one proband and co-segregated in two affected half-siblings, with mosaicism in the healthy mother. Using a specific ouabain resistance assay in mutant transfected HEK cells, we found significantly reduced cell viability. Demonstrating loss of ATPase function, we conclude that this novel variant is pathogenic, expanding the phenotype spectrum of ATP1A1.
PMID:38504481 | DOI:10.1002/acn3.51963
Add to Google Keep
Post to X
Share on Linkedin
Estimated reading time: 3 minute(s)
Latest: Psychiatryai.com #RAISR4D
Cool Evidence: Engaging Young People and Students in Real-World Evidence ☀️
Real-Time Evidence Search [Psychiatry]
AI Research [Andisearch.com]
Recurrent ATP1A1 variant Gly903Arg causes developmental delay, intellectual disability, and autism
🌐 90 Days
VR Related Evidence Matrix
Evidence Blueprint
Recurrent ATP1A1 variant Gly903Arg causes developmental delay, intellectual disability, and autism
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
Recurrent ATP1A1 variant Gly903Arg causes developmental delay, intellectual disability, and autism
🌐 365 Days
VR Related Evidence Matrix
